Biogen announced it will acquire Human Immunology Biosciences, also known as HI-Bio, in a deal valued at up to $1.8 billion. The purchase includes felzartamab, an asset designed to treat primary membranous nephropathy, a rare type of kidney disease, increasing Biogen's inventory of rare disease medications.